During 72 weeks of treatment, people taking tirzepatide at doses of 5, 10, or 15 mg lost an average of 15.0%, 19.5%, and 20.9%, respectively, compared with just 3.1% in people taking a placebo
And it usually gets easier once you adjust to the side effects
The long-term impact of widespread use of these drugs, particularly if complications arise could strain resources further
In operationalizing the Medicare Part B Drug Inflation Rebate Program for the first time, we have adopted this clarification with further refinements in our approach to ensure timely and appropriate manufacturer identification by taking into account, as applicable, manufacturer-identifying information in other government systems, including MDRP, and other public sources
Niwa-Kawakita, M
doi: 10.1016/j.yexcr.2020.112056 [DOI] [PMC free article] [PubMed] [Google Scholar] 24